TPIV may start heating up again. Several key catalyst are coming up.
3Q 2017: Publish long-term safety, immune response and survival data from completed Phase 1 clinical study of TPIV 200 3Q 2017: Report interim results from ongoing Phase 2 study of TPIV 200 in combination with AstraZeneca's durvalumab in patients with platinum-resistant ovarian cancer 3Q 2017: Mayo Clinic to initiate 280-patient Phase 2 study of TPIV 200 in women with advanced triple-negative breast cancer 3Q 2017: On track to complete enrollment in Phase 2 dosing study of TPIV 200 in TNBC 4Q 2017: TPIV 100/110 File amended IND; initate phase 1b/2 HER2/neu + breast cancer study 4Q 2017/1Q 2018- TPIV100/110 Mayo Clinic to initate Phase 1b/2 HER2/nue + DCIS study Year end 2017: File amended investigational new drug application (IND) for TPIV 110 for treating HER2/neu+ breast cancer.
Additionally: ACCRU study is now listed as status= "OPEN" (RU011501I)
Responsible Party: Academic and Community Cancer Research United ClinicalTrials.gov Identifier: NCT03012100 History of Changes Other Study ID Numbers: RU011501I NCI-2016-01878 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) ) RU011501I ( Other Identifier: Academic and Community Cancer Research United ) P30CA015083 ( U.S. NIH Grant/Contract )
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.